Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma

Pulmonary Pharmacology and Therapeutics

Volumn 29, Issue 1, 2014, Pages 15-23

  Barchuk, W ^a   Lambert, J ^b   Fuhr, R ^b   Jiang, J Z ^a   Bertelsen, K ^c   Fourie, A ^a   Liu, X ^a   Silkoff, P E ^a   Barnathan, E S ^a   Thurmond, R ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b PAREXEL INTERNATIONAL   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Asthma; Hypersensitivity; Leukotriene antagonist; Leukotriene synthesis inhibitor; Montelukast

Indexed keywords

ALLERGEN; BRONCHIAL ALLERGEN; CALCIMYCIN; JNJ 40929837; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NITRIC OXIDE; PLACEBO; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; EPOXIDE HYDROLASE; JNJ-40929837; LEUKOTRIENE B4; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE; TROPANE DERIVATIVE;

ADULT; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CAT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DUST; DYSPNEA; ELECTROCARDIOGRAPHY MONITORING; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; GRASS; HEADACHE; HUMAN; MALE; MORNING DOSAGE; NAUSEA; NEUTROPHIL COUNT; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRICK TEST; PRIORITY JOURNAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SPUTUM; TABLET; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; INHALATION TEST; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ACETATES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL PROVOCATION TESTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EPOXIDE HYDROLASES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE B4; MALE; QUINOLINES; SPUTUM; THIAZOLES; TREATMENT OUTCOME; TROPANES; YOUNG ADULT;

EID: 84906933654     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.06.003     Document Type: Article

References (33)

1. Busse W.W., Lemanske R.F. Asthma. N Engl J Med 2001, 344(5):350-362.
2. Holgate S.T., Arshad H.S., Roberts G.C., Howarth P.H., Thurner P., Davies D.E. Anew look at the pathogenesis of asthma. Clin Sci (Lond) 2010, 118(7):439-450.
3. Tager A.M., Luster A.D. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids 2003, 69(2-3):123-134.
4. Toda A., Yokomizo T., Shimizu T. Leukotriene B4 receptors. Prostaglandins Other Lipid Mediat 2002, 68-69:575-585.
5. Miyahara N., Takeda K., Miyahara S., Matsubara S., Koya T., Joetham A., et al. Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. Am J Respir Crit Care Med 2005, 172(2):161-167.
6. Terawaki K., Yokomizo T., Nagase T., Toda A., Taniguchi M., Hashizume K., et al. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. JImmunol 2005, 175(7):4217-4225.
7. Turner C.R., Breslow R., Conklyn M.J., Andresen C.J., Patterson D.K., Lopez-Anaya A., et al. Invitro and invivo effects of leukotriene B4 antagonism in a primate model of asthma. JClin Invest 1996, 97(2):381-387.
8. Dahlen S.E. Treatment of asthma with antileukotrienes: first line or last resort therapy?. Eur J Pharmacol 2006, 533(1-3):40-56.
9. Rao N.L., Riley J.P., Banie H., Xue X., Sun B., Crawford S., et al. Leukotriene A(4) hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2010, 181(9):899-907.
10. Tanis V.M., Bacani G.M., Blevitt J.M., Chrovian C.C., Crawford S., De Leon A., et al. Azabenzthiazole inhibitors of leukotriene A(4) hydrolase. Bioorg Med Chem Lett 2012, 22(24):7504-7511.
11. Laszlo G. Standardisation of lung function testing: helpful guidance from the ATS/ERS task force. Thorax 2006, 61(9):744-746.
12. Jian W., Edom R.W., Xue X., Huang M.Q., Fourie A., Weng N. Quantitation of leukotriene B(4) in human sputum as a biomarker using UPLC-MS/MS. JChromatogr B Analyt Technol Biomed Life Sci 2013, 932:59-65.
13. Lin W., Huang M.Q., Xue X., Bertelsen K., Chen G., Zhao H., et al. Ahighly sensitive and selective method for the determination of leukotriene B4 (LTB4) in exvivo stimulated human plasma by ultra fast liquid chromatography-tandem mass spectrometry. JChromatogr B Analyt Technol Biomed Life Sci 2013, 925:54-62.
14. Hill A.V. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. JPhysiol 1910, 40:iv-vii.
15. Leigh R., Vethanayagam D., Yoshida M., Watson R.M., Rerecich T., Inman M.D., et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 2002, 166(9):1212-1217.
16. Hamelmann E., Schwarze J., Takeda K., Oshiba A., Larsen G.L., Irvin C.G., et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997, 156(3 Pt 1):766-775.
17. Zosky G.R., Larcombe A.N., White O.J., Burchell J.T., Janosi T.Z., Hantos Z., et al. Ovalbumin-sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation. Clin Exp Allergy 2008, 38(5):829-838.
18. Li S., Aliyeva M., Daphtary N., Martin R.A., Poynter M.E., Kostin S.F., et al. Antigen-induced mast cell expansion and bronchoconstriction in a mouse model of asthma. Am J Physiol Lung Cell Mol Physiol 2014, 306(2):L196-L206.
19. Tognella S., Micheletto C., Visconti M.P., Dal Negro R.W. ADditive effects of montelukast on bronchial hyperresponsiveness to MCh and lte4 urine levels in mild-persistent atopic asthmatics assuming ICS. CHEST J 2004, 126. (4_MeetingAbstracts):814S-b-S.
20. Yao H.Z.P., Wang X., Wang W., Liu S., Chen X. Effect of montelukast on the level of urine leukotriene E4 in children with bronchiolitis. Chin J Clin Pharmacol Ther 2012, (4):441-444.
21. Evans D.J., Barnes P.J., Spaethe S.M., van Alstyne E.L., Mitchell M.I., O'Connor B.J. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996, 51(12):1178-1184.
22. Yokomizo T., Kato K., Terawaki K., Izumi T., Shimizu T. Asecond leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. JExp Med 2000, 192(3):421-432.
23. Davis B.E., Illamperuma C., Gauvreau G.M., Watson R.M., O'Byrne P.M., Deschesnes F., et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J 2009, 33(6):1302-1308.
24. Diamant Z., Grootendorst D.C., Veselic-Charvat M., Timmers M.C., De Smet M., Leff J.A., et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999, 29(1):42-51.
25. Richter K., Gronke L., Janicki S., Maus J., Jorres R.A., Magnussen H. Effect of azelastine, montelukast, and their combination on allergen-induced bronchoconstriction in asthma. Pulm Pharmacol Ther 2008, 21(1):61-66.
26. Friedman B.S., Bel E.H., Buntinx A., Tanaka W., Han Y.H., Shingo S., et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993, 147(4):839-844.
27. Hamilton A.L., Watson R.M., Wyile G., O'Byrne P.M. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997, 52(4):348-354.
28. Jatakanon A., Uasuf C., Maziak W., Lim S., Chung K.F., Barnes P.J. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999, 160(5 Pt 1):1532-1539.
29. Noguera A., Batle S., Miralles C., Iglesias J., Busquets X., MacNee W., et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001, 56(6):432-437.
30. Sagel S.D., Kapsner R., Osberg I., Sontag M.K., Accurso F.J. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001, 164(8 Pt 1):1425-1431.
31. Fanta C.H., Long A.A. Difficult asthma: assessment and management, part 2. Allergy Asthma Proc 2012, 33(4):313-323.
32. Long A.A., Fanta C.H. Difficult asthma: assessment and management, part 1. Allergy Asthma Proc 2012, 33(4):305-312.
33. Snelgrove R.J., Jackson P.L., Hardison M.T., Noerager B.D., Kinloch A., Gaggar A., et al. Acritical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010, 330(6000):90-94.